Methyltestosterone

Methyltestosterone is testosterone with a single structural modification — a methyl group at the C17α position — and nearly everything interesting about it flows from that one change. It's a full androgen receptor agonist with the same downstream signalling as endogenous test, but the 17α-methyl group rewrites its pharmacokinetics and metabolic fate in ways that matter practically for dosing, estrogen control, and liver risk.

17α-Alkylation and Oral Bioavailability#

The methyl group at C17α sterically blocks hepatic oxidation of the 17β-hydroxyl — the site the liver normally attacks to inactivate testosterone on first pass. Block that reaction and the molecule survives the portal circulation intact, producing meaningful serum androgen levels from an oral dose where plain testosterone gives you essentially nothing.

"The methyl group in position 17-alpha is responsible for the high bioavailability of methyltestosterone after oral administration." — Cravedi JP et al., Aquat Toxicol, 2001

Practical consequence: ~70% oral bioavailability, Tmax around 1–2 hours, and an elimination half-life of 2.5–3.5 hours. That short half-life is why modern users dose it pre-workout as a buccal troche — you get an acute peak, train on it, and it's mostly cleared by the time you're home. It's also why it was historically prescribed TID rather than QD.

Androgen Receptor Agonism#

Once in circulation, methyltestosterone binds the androgen receptor with affinity comparable to testosterone, triggering the standard AR → nuclear translocation → androgen-response-element transcription cascade: upregulated muscle protein synthesis, erythropoiesis, IGF-1 signalling in muscle, and CNS effects (aggression, drive, libido). The anabolic:androgenic ratio is roughly 100:100 — i.e. no tissue selectivity versus testosterone itself. You get the full androgenic profile (acne, oily skin, scalp pressure if you're MPB-prone, prostate signalling) in exact proportion to the anabolic effect, which is why it doesn't punch above its weight the way oxandrolone or primobolan do on a mg-for-mg basis.

Aromatization to 17α-Methylestradiol#

Methyltestosterone is aromatized by CYP19 into 17α-methylestradiol — and this is the mechanism behind its outsized estrogenic footprint. The methyl group that protects the C17 position against hepatic oxidation also protects the estrogen metabolite against normal clearance, so 17α-methylestradiol has a longer functional half-life and a more potent estrogenic signal than regular E2.

"Methyltestosterone is rapidly aromatized in the body to 17α-methylestradiol, a potent estrogen with a longer half-life than estradiol, resulting in more pronounced oestrogenic adverse effects." — Grant B et al., Ann NY Acad Sci, 2024

Two practical implications:

1. Gyno risk and water retention are disproportionate to the androgen dose — expect more bloat and nipple sensitivity per mg than you'd get from test E.
2. AIs like anastrozole work poorly here. They reduce aromatase activity upstream, but the methylated estrogen that's already been made clears slowly. SERM coverage (raloxifene 60 mg, or tamoxifen 10–20 mg) is what actually rescues gyno on this compound.

5α-Reduction to Mestanolone#

A fraction of methyltestosterone is 5α-reduced to mestanolone (17α-methyl-DHT), a potent AR agonist in androgenic tissues. This drives the DHT-pathway sides — scalp follicle miniaturization in MPB-prone users, sebaceous gland activity (acne, oily skin), and prostate signalling. Finasteride only partially blunts this because the substrate is 17α-methylated; dutasteride covers more ground. For hair-retention-focused users, topical AR antagonists (RU58841, pyrilutamide) remain the more reliable defense on any androgen-heavy cycle.

Hepatic Load: The Cost of Orality#

The same 17α-methyl group that gives you oral bioavailability is the group responsible for hepatotoxicity. Because the liver can't oxidize the C17 position, the molecule lingers in hepatocytes longer than unmodified androgens, stressing biliary transport proteins and driving cholestatic patterns before classical cytolysis shows up on labs.

"Liver damage is primarily associated with 17α-alkylated androgens such as methyltestosterone, and symptoms may present after only a few weeks of use." — Skrzypiec-Spring M et al., J Clin Med, 2024

Documented outcomes in the case-report literature go beyond raised enzymes: cholestatic jaundice, peliosis hepatis, and hepatocellular adenomas (with rupture cases reported) appear at doses and durations that aren't extreme by bodybuilding standards (Solbach et al., 2022). This is the hard ceiling on how you use the compound — short blocks, pre-workout-only dosing where possible, TUDCA + NAC liver support, and never stacked with another 17α-alkylated oral. The liver risk from two methyls run together multiplies rather than adds.

Common (most users)#

• Estrogenic bloat and puffy look — the 17α-methylestradiol metabolite is the driver here, and it resists AI control more stubbornly than regular E2. Keep sodium in check, run raloxifene 60mg or tamoxifen 10–20mg on hand rather than leaning on anastrozole alone (Grant et al., 2024).
• Elevated liver enzymes (AST/ALT) — expected on any 17α-alkylated oral. Baseline LFTs, re-check at week 3–4. TUDCA 500–1000mg/day + NAC 1200–1800mg/day is standard. Avoid alcohol entirely during the block.
• Blood pressure creep — monitor at home morning and evening. A few readings above 140/90 is your cue to pull dose or add telmisartan. Don't ignore this; dbol/MT users who chart BP catch problems weeks before symptoms.
• Oily skin and acne — mestanolone (17α-methyl-DHT) is the culprit. Nizoral 2% on affected areas, benzoyl peroxide, and keeping the block short (4–6 weeks) keeps it manageable.
• Aggression / tunnel vision pre-workout — most users consider this a feature; becomes a bug if it bleeds into non-training hours. Dose only on lift days.
• Libido swings — usually up initially, then flat as HPTA suppresses. A TRT base solves this; running MT standalone doesn't.

Uncommon (dose-dependent or individual)#

• Gynecomastia — itchy or puffy nipples at any point means pull the trigger on raloxifene immediately. AIs alone often don't rescue gyno on this compound because methylated estrogen doesn't clear the same way:

"Methyltestosterone is rapidly aromatized in the body to 17α-methylestradiol, a potent estrogen with a longer half-life than estradiol, resulting in more pronounced oestrogenic adverse effects." — Grant et al., 2024

• Lipid disruption (HDL crash, LDL spike) — 17α-alkyls hit HDL hard. Get a lipid panel mid-cycle; if HDL drops below 25 or LDL crosses 160, shorten the block or drop dose. Citrus bergamot and omega-3s help the magnitude but don't erase it.
• Cholestatic jaundice — yellowing of skin/eyes, dark urine, pale stools, itching. Stop immediately and get LFTs + GGT + bilirubin. This can show up in weeks, not months:

"Liver damage is primarily associated with 17α-alkylated androgens such as methyltestosterone, and symptoms may present after only a few weeks of use." — Skrzypiec-Spring et al., 2024

• Accelerated male pattern baldness — predisposed users will notice shedding within the cycle. Topical finasteride or RU58841 helps; oral finasteride will NOT block the 17α-methyl-DHT metabolite the same way it blocks endogenous DHT.
• Insomnia / elevated resting heart rate — typically dose-related. Back off to 10–15mg or cut frequency to 2×/week.
• Prostate symptoms — hesitancy, weak stream, nocturia. PSA baseline is smart for anyone over 35.

Rare but serious#

• Hepatic adenomas and peliosis hepatis — blood-filled hepatic cysts and benign liver tumors, both documented with methyltestosterone specifically. Warning signs: right-upper-quadrant pain, unexplained fatigue, abdominal fullness. Stop and get imaging:

"Several case reports have implicated methyltestosterone in the development of hepatic adenomas and peliosis hepatis, highlighting significant hepatotoxic risks." — Solbach et al., 2022

• Hepatic adenoma rupture — sudden severe abdominal pain with hypotension is a surgical emergency. Rare but catastrophic; it's why 8+ week blocks at 30mg+ daily are not worth running.
• Polycythemia — hematocrit above 54% raises stroke/clot risk. Check CBC mid-cycle; therapeutic phlebotomy or blood donation resolves it.
• Cardiac events — LVH and adverse remodeling are documented with chronic oral AAS use. Short blocks minimize but don't zero this out.
• Severe acne (conglobata, fulminans) — rare but can scar. Dermatologist + dose cut immediately.

Hard contraindications#

• Active liver disease, hepatitis, biliary obstruction, or elevated baseline LFTs — methyltestosterone is off the table. Pick an injectable.
• Prostate cancer or male breast cancer — absolute.
• Untreated hypertension or dyslipidemia — get these controlled before any 17α-alkyl oral. Non-negotiable.
• Pregnancy / women trying to conceive — Category X, teratogenic.
• Concurrent 17α-alkylated orals (superdrol, anadrol, winstrol, halotestin, dbol) — stacking methyls multiplies hepatotoxicity, not adds. One oral at a time.
• Alcohol use during the cycle — the liver is already working overtime. Stop drinking for the duration.
• Tested athletes — metabolites persist for weeks and the WADA screens catch them cleanly:

"Metabolites of methyltestosterone, such as 17α-methyl-androsterone and 17α-methyl-etiocholanolone, are detectable in urine for weeks following administration." — Mazzarino et al., 2022

Gender considerations and PCT#

Women should not run methyltestosterone. The virilization threshold is low (voice deepening, clitoromegaly, jaw changes) and because the 17α-methyl group extends metabolite persistence, sides can cement before they're caught. For women wanting an oral, anavar is the only sensible choice in this class.

PCT is required on any cycle crossing ~2 weeks of daily use or ~3–4 weeks of regular pre-workout dosing. Standard protocol starts ~3 days after last dose (short half-life clears fast):

If running with a test base, PCT follows the base ester's clearance timeline, not methyltestosterone's. Bloodwork 4–6 weeks post-PCT confirms recovery — don't skip this step.